Journal
BLOOD
Volume 114, Issue 1, Pages 144-147Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2009-03-210039
Keywords
-
Categories
Funding
- Howard Hughes Medical Institute Funding Source: Medline
- NCI NIH HHS [U10 CA021115, U24 CA114737, R01 CA101774-07, CA10863101, R01 CA101774] Funding Source: Medline
- NHLBI NIH HHS [HL082677, K08 HL082677] Funding Source: Medline
Ask authors/readers for more resources
Disease alleles that activate signal transduction are common in myeloid malignancies; however, there are additional unidentified mutations that contribute to myeloid transformation. Based on the recent identification of TET2 mutations, we evaluated the mutational status of TET1, TET2, and TET3 in myeloproliferative neoplasms (MPNs), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). Sequencing of TET2 in 408 paired tumor/normal samples distinguished between 68 somatic mutations and 6 novel single nucleotide polymorphisms and identified TET2 mutations in MPN (27 of 354, 7.6%), CMML (29 of 69, 42%), AML (11 of 91, 12%), and M7 AML (1 of 28, 3.6%) samples. We did not identify somatic TET1 or TET3 mutations or TET2 promoter hypermethylation in MPNs. TET2 mutations did not cluster in genetically defined MPN, CMML, or AML subsets but were associated with decreased overall survival in AML (P = .029). These data indicate that TET2 mutations are observed in different myeloid malignancies and may be important in AML prognosis. (Blood. 2009; 114:144-147)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available